Evercore ISI Group Maintains Outperform on NovoCure, Lowers Price Target to $20

Benzinga · 1d ago
Evercore ISI Group analyst Vijay Kumar maintains NovoCure (NASDAQ:NVCR) with a Outperform and lowers the price target from $23 to $20.